Fred Hutch leaders raise $10M for new AI startup aiming to expedite drug discovery

Jeff Leek (left) and Robert Bradley, co-founders of Synthesize Bio and researchers at Fred Hutchinson Cancer Center. (LinkedIn Photo)Synthesize Bio, a Seattle-based startup founded by leaders from Fred Hutchinson Cancer Center, announced $10 million in funding from Madrona Venture Group. “With generative genomics, researchers can ask bolder questions, design smarter trials, and test hypotheses that were previously unaffordable or impossible to explore.”An illustration of how the Synthesize Bio technology works. (Synthesize Bio)In its preprint article, the Synthesize Bio team elaborated on the problem it is trying to solve. Synthesize Bio, for example, could help researchers whose drug candidates have cleared clinical safety testing assess whether those therapies are also likely to deliver meaningful health benefits.